title: Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer.
abstract: In the present study, clinical tumor response following neoadjuvant chemotherapy (NAC) was diagnosed by magnetic resonance imaging (MRI) and clinicopathological factors, including molecular subtypes at baseline, were analyzed for correlations with pathological tumor responses. In addition, clinicopathological factors were analyzed for a correlation with the MRI capacity to predict pathological complete response (pCR). Clinical tumor response evaluated by MRI following NAC was determined as a clinical CR (cCR) or a residual tumor. cCR was confirmed if no gadolinium enhancement or an enhancement equal to or less than that of glandular tissue was observed in any phase of the MRI. Pathological tumor responses following NAC were classified into grades 0 (no change) to 3 (no residual invasive cancer) according to criteria of the Japanese Breast Cancer Society. pCR was defined as grade 3 in the present study. Of 264 cases of invasive breast cancer in 260 patients (4 synchronous bilateral breast cancer cases), 59 (22%) were diagnosed by MRI following NAC as cCR and 98 (37%) were pathologically diagnosed as pCR. In terms of predicting pCR by MRI, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were 44, 90, 73, 73 and 73%, respectively. Tumor size, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, molecular subtype and histological type were significantly correlated with pathological tumor responses. pCR rates increased in the following order: luminal/HER2-negative (14%), luminal/HER2-positive (32%), triple-negative (46%) and non-luminal/HER2-positive (73%) tumors. Sensitivity and specificity were the highest (60 and 100%, respectively) in triple-negative tumors. PPV decreased in the following order: triple-negative (100%), non-luminal/HER2-positive (92%), luminal/HER2-positive (46%) and luminal/HER2-negative (33%) tumors. In conclusion, MRI evaluation is useful for predicting pCR following NAC, particularly for triple-negative tumors.
authors.affiliation: Division of Breast Surgery, Saitama Cancer Center, Saitama 362-0806; ; Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University, Gunma 371-8511;
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takei
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nozu
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tochigi
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ichikawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kurosumi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Inoue
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Shigenori E
authors.initials: SE
authors.lastname: Nagai
authors.forename: Hanako
authors.initials: H
authors.lastname: Oba
authors.forename: Toshio
authors.initials: T
authors.lastname: Tabei
authors.forename: Jun
authors.initials: J
authors.lastname: Horiguchi
authors.forename: Izumi
authors.initials: I
authors.lastname: Takeyoshi